ADC Therapeutics (ADCT) lost more than 50% in the premarket on Thursday as Wall Street reacted to topline data from a ...

Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the ...

Adults with mantle cell lymphoma who have already failed two or more treatments, including a BTK inhibitor, now have a new ...

In an ongoing Phase 1 study of 12 patients with relapsed or refractory B-cell non-Hodgkin lymphoma, Legend Biotech's CAR-T cell therapy LB2501 demonstrated a 100% objective response rate and an 83% ...

SunMo demonstrated superior progression-free survival and overall response for mosunetuzumab plus polatuzumab vedotin versus ...

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs ...

Patients with T-cell acute lymphoblastic leukaemia (T-ALL) and the closely related peripheral T-cell lymphoblastic lymphoma ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

St. David's South Austin enrolled the first patient in a global lymphoma therapy study using a next-generation CAR T approach ...

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI ...

Hodgkin lymphoma and primary mediastinal B-cell lymphoma are two aggressive blood cancers that affect young people between their late teens and mid-30s, a group often referred to as Adolescents and ...

For some subtypes of non-Hodgkin lymphoma, you may get a targeted therapy. This is more exact than standard chemotherapy, which affects all fast-growing cells in the body. Small molecule inhibitors ...